NASUS PHARMA LTD (NSRX) Fundamental Analysis & Valuation

NYSEARCA:NSRX • IL0012181553

Current stock price

2.25 USD
+0.04 (+1.81%)
Last:

This NSRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. NSRX Profitability Analysis

1.1 Basic Checks

  • In the past year NSRX has reported negative net income.
  • NSRX had a negative operating cash flow in the past year.
NSRX Yearly Net Income VS EBIT VS OCF VS FCFNSRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -1K -2K -3K -4K

1.2 Ratios

  • With a Return On Assets value of -442.86%, NSRX is not doing good in the industry: 95.29% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -442.86%
ROE N/A
ROIC N/A
ROA(3y)-605.95%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NSRX Yearly ROA, ROE, ROICNSRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

  • NSRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NSRX Yearly Profit, Operating, Gross MarginsNSRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. NSRX Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for NSRX remains at a similar level compared to 1 year ago.
  • There is no outstanding debt for NSRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NSRX Yearly Shares OutstandingNSRX Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2M 4M 6M 8M
NSRX Yearly Total Debt VS Total AssetsNSRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 200 400 600

2.2 Solvency

  • NSRX has an Altman-Z score of 3939.80. This indicates that NSRX is financially healthy and has little risk of bankruptcy at the moment.
  • NSRX's Altman-Z score of 3939.80 is amongst the best of the industry. NSRX outperforms 99.48% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 3939.8
ROIC/WACCN/A
WACCN/A
NSRX Yearly LT Debt VS Equity VS FCFNSRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 -1K -2K -3K

2.3 Liquidity

  • NSRX has a Current Ratio of 0.13. This is a bad value and indicates that NSRX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Current ratio value of 0.13, NSRX is not doing good in the industry: 96.86% of the companies in the same industry are doing better.
  • A Quick Ratio of 0.13 indicates that NSRX may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.13, NSRX is doing worse than 96.34% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.13
Quick Ratio 0.13
NSRX Yearly Current Assets VS Current LiabilitesNSRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 1K 2K 3K 4K

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. NSRX Growth Analysis

3.1 Past

  • NSRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -50.00%.
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -1607.42% on average over the next years. This is quite bad
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-232800%
EPS Next 2Y-7320.44%
EPS Next 3Y-1607.42%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NSRX Yearly EPS VS EstimatesNSRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 -0.5 -1 -1.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. NSRX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Forward Price/Earnings Ratio is negative for NSRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NSRX Price Earnings VS Forward Price EarningsNSRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NSRX Per share dataNSRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.2 -0.4 -0.6

4.3 Compensation for Growth

  • A cheap valuation may be justified as NSRX's earnings are expected to decrease with -1607.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7320.44%
EPS Next 3Y-1607.42%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NSRX Dividend Analysis

5.1 Amount

  • No dividends for NSRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NSRX Fundamentals: All Metrics, Ratios and Statistics

NASUS PHARMA LTD

NYSEARCA:NSRX (4/16/2026, 11:13:44 AM)

2.25

+0.04 (+1.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners0.02%
Inst Owner Change0%
Ins Owners33.83%
Ins Owner Change0.39%
Market Cap26.35M
Revenue(TTM)N/A
Net Income(TTM)-3.10K
Analysts82.5
Price Target20.4 (806.67%)
Short Float %1.7%
Short Ratio0.49
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.44%
PT rev (3m)-2.44%
EPS NQ rev (1m)3.61%
EPS NQ rev (3m)6.98%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)0
EYN/A
EPS(NY)-0.7
Fwd EYN/A
FCF(TTM)0
FCFYN/A
OCF(TTM)0
OCFYN/A
SpS0
BVpS0
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -442.86%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-605.95%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.13
Quick Ratio 0.13
Altman-Z 3939.8
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y-232800%
EPS Next 2Y-7320.44%
EPS Next 3Y-1607.42%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y4.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y38.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.1%
OCF growth 3YN/A
OCF growth 5YN/A

NASUS PHARMA LTD / NSRX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of NASUS PHARMA LTD (NSRX) stock?

ChartMill assigns a fundamental rating of 1 / 10 to NSRX.


What is the valuation status for NSRX stock?

ChartMill assigns a valuation rating of 0 / 10 to NASUS PHARMA LTD (NSRX). This can be considered as Overvalued.


What is the profitability of NSRX stock?

NASUS PHARMA LTD (NSRX) has a profitability rating of 0 / 10.


Can you provide the financial health for NSRX stock?

The financial health rating of NASUS PHARMA LTD (NSRX) is 2 / 10.